DGAP-News: MOLOGEN AG / Key word(s): Change of Personnel
MOLOGEN AG appoints Dr. Stefan M. Manth to the scientific advisory
board
18.11.2011 / 09:00
---------------------------------------------------------------------
Berlin, November 18, 2011 - The biotechnology company MOLOGEN AG has
expanded its scientific advisory board. With Stefan M. Manth, MD, PhD, MBA,
the advisory committee has been joined by a top manager from the
pharmaceutical industry with extensive experience in the strategic
development and marketing of innovative medicines.
Dr. Manth, who works as an independent consultant for pharmaceutical and
biotechnology companies on operational issues and strategic matters, has
previously workedfor over two decades for the Roche Group. He brings with
him extensive international experience, and played an instrumental role in
the successful development of the Oncology business at
Roche/Genentech/Chugai. For MOLOGEN AG, whose first projects have entered
advanced stages of clinical development, Dr. Manth's professional
background represents a crucial enrichment of the scientific advisory
board's portfolio of expertises.
Prof. Dr. Burghardt Wittig, chairman of the scientific advisory board and
co-founder of MOLOGEN AG, greatly welcomes the committee's expansion. 'We
need the best to tackle the issues at hand to help MOLOGEN attain 'best in
class'-status. I am delighted that with Dr. Stefan Manth, we have, in this
important first licensing phase, been able to access expertise that had
been absent from our advisory board up to this point. Here, his competence
with the strategic interdependence of scientific, clinical and regulatory
issues is of enormous value to the scientific advisory board.'
Dr. Stefan M. Manth: 'It is a great pleasure and honor for me to work with
the scientific advisory board of MOLOGEN AG and to advise and support a
team of extraordinarily talented managers and researchers in their
important mission. I am very enthusiastic about the, in my view, unique
immunotherapeutic approach that MOLOGEN AG is taking to treat cancer. Three
Nobel prizes for Medicine in 2011 are a truly excellent confirmation of
this distinguished approach. In order to make it accessible to a large
number of cancer patients, MOLOGEN AG has to successfully face and master
all important challenges in the final phases of clinical development. I am
happy to contribute my diverse experiences and knowledge to this endeavor.'
The scientific advisory board of MOLOGEN AG
The scientific advisory board of MOLOGEN AG is a committee of respected,
internationally acknowledged scientists in the fields of molecular
medicine, infectious diseases and/or cancer diseases as well as experts in
their field. It advises the Board of Directors on fundamental scientific
procedures, new technologies and fields of business.
It currently comprises five members:
Prof. Dr. Burghardt Wittig, Germany
Chairman of the Scientific Advisory Board
Co-founder and former CEO of MOLOGEN AG
Professor for molecular biology and bioinformatics at the Freie Universität
Berlin
Prof. em. Dr. Hans Lutz, FVH, FAMH, Switzerland
Vice Chairman of the Scientific Advisory Board
Professor for clinical laboratory diagnostics and head of the veterinary
medicinal laboratory, Vetsuisse faculty, University of Zurich
Dr. Ulrich Granzer, Germany
Founder and CEO of Granzer Regulatory Consulting & Services, Munich
Dr. med. Stefan M. Manth, Switzerland
Independent expert for pharma and biotechnology
Dr. med. habil. Martin Weihrauch, Germany
Board certified Internist, Hematologist and Oncologist at the Center for
Intergrated Oncology and Medical Director of the outpatient department
(MVZ) at the University Clinic, Cologne
www.mologen.com.
About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin
specializes in the research and development of innovative medications on
the basis of DNA structures. The activities focus on numerous product
developments which are relevant to the immune system; on the one hand
vaccines against infectious diseases and on the other hand cancer
medications. MOLOGEN AG is globally one of the few biotechnology companies
with well tolerated DNA-based cancer treatment in the clinical development
phase.
The stocks of MOLOGEN AG are listed in the Prime Standard of the German
stock exchange (ISIN DE0006637200).
Memberships in associations:
BIO Deutschland e.V. | DECHEMA - Society for chemical technology and
biotechnology e.V. | German industrial association of biotechnology (DIB)
| Association for the Promotion of Science and Humanities in Germany |
Association of German biotechnology companies (VBU) | Association of
researching manufacturers of pharmaceuticals e.V. (VFA) | Association of
the chemical industry e.V. (VCI)
MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE:
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner@mologen.com
INVESTOR RELATIONS:
Joerg Petrass
Tel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor@mologen.com
External Investor Relations:
Kirchhoff Consult AG
Sebastian Bucher
T: +49 - 40 - 60 91 86 - 18
F: +49 - 40 - 60 91 86 -16
sebastian.bucher@kirchhoff.de
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation..
End of Corporate News
---------------------------------------------------------------------
18.11.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
146898 18.11.2011
